AcelRx Pharmaceuticals(ACRX) - 2024 Q4 - Annual Results

Exhibit 99.1 Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registrational NEPHRO CRRT study to be completed by the end of 2025 Cash and investments at December 31, 2024 of $8.9 million, together with the private placement financing recently announced of up to $14.8 million, expected to provide capital through t ...